FilingReader Intelligence
Hengrui Medicine drugs gain breakthrough therapy designation
August 11, 2025 at 05:06 PM UTC•By FilingReader AI
Jiangsu Hengrui Medicine's subsidiaries announced that their drugs SHR-A1811 and Aidbelymab injection have been listed as proposed breakthrough therapies by China's National Medical Products Administration.
The designation covers the combination treatment for specific types of breast cancer. This marks the ninth breakthrough therapy designation for SHR-A1811.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Jiangsu Hengrui Medicine publishes news
Free account required • Unsubscribe anytime